EARS Auris Medical Holding AG

0.77
+0  (3%)
Previous Close 0.75
Open 0.74
Price To book 1.83
Market Cap 26.43M
Shares 34,329,000
Volume 83,732
Short Ratio 0.53
Av. Daily Volume 556,890

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Open label safety trial data due 2Q 2017.
Keyzilen (AM-101) - AMPACT open-label
Acute inner ear tinnitus
Phase 3 HEALOS data due 3Q 2017.
AM-111 HEALOS
Acute inner ear hearing loss
Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line results expected in early 2018.
Keyzilen (AM-101) - TACTT3
Acute inner ear tinnitus
Phase 3 ASSENT data due 2H 2018.
AM-111 ASSENT
Acute inner ear hearing loss
Phase 2 trial (REACH) to begin enrollment in 1H 2017 pending funding
AM-111 REACH
Surgery-induced hearing loss
Phase 3 trial did not meet primary endpoints
AM-101 (Keyzilen) - TACTT2
Acute inner ear tinnitus

Latest News

  1. Two-horse race: Auris, Otonomy seek FDA nod for inner-ear therapies
  2. Auris Medical Announces Receipt of Nasdaq Notice of Bid Price Deficiency
  3. Auris Medical to Present at the 16th Annual Needham Healthcare Conference on April 5
  4. Edited Transcript of EARS earnings conference call or presentation 14-Mar-17 12:00pm GMT
  5. Auris Medical Provides Business Update and Reports Full Year 2016 Financial Results
  6. Auris Medical to Present at the 29th Annual Roth Conference on March 14
  7. Auris Medical to Announce Full Year 2016 Financial Results and Host Conference Call on March 14
  8. Auris Medical Receives FDA Fast Track Designation for AM-111 in Acute Sensorineural Hearing Loss
  9. Auris Medical and King's College London Extend Tinnitus Collaboration
  10. Auris Medical Announces Closing of $10 Million Public Offering
  11. Auris Medical Announces Pricing of $10 Million Public Offering
  12. Auris Medical Announces Proposed Public Offering of Common Shares and Warrants
  13. Auris (EARS) Expands Pipeline with Intranasal Betahistine
  14. Blog Coverage Auris Medical Expands Clinical Development Pipeline for Treatment of Meniere's Disease and Vestibular Vertigo
  15. Auris Medical Expands Clinical Development Pipeline with Intranasal Betahistine for the Treatment of Meniere's Disease and Vestibular Vertigo
  16. Auris Medical to Announce Business Update and Host Conference Call and Webcast Tomorrow, February 3, 2017
  17. Auris Medical Resumes Enrollment in TACTT3 Phase 3 Trial of Keyzilen in Acute and Post-Acute Tinnitus